- Global Pharma News & Resources

Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Estimation 2020 – Latest Trends, Country Level Analysis, Growth, Newly Invented Strategies, Opportunities, Drivers, Challenges and Influence Factors Shared in Latest Report

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that are responsible for controlling the voluntary muscles of the body. The disease is progressive in nature and worsens over time.

According to a study published by the Centers for Disease Control and Prevention (CDC) in 2016, around 14,713 people were diagnosed with ALS in the U.S., and in 2012, the prevalence rate of ALS was 4.7 cases per 100,000 people. The prevalence rate increased to 5.0 cases per 100,000 people and around 15,908 people were diagnosed with ALS in 2013, according to the same study. The increasing prevalence of ALS is, in turn, expected to support growth of the global amyotrophic lateral sclerosis (ALS) treatment market in the near future.

Request Sample Copy of the Business Report:

Approval of novel innovative drugs is expected to boost the global market growth

In May 2017, The U.S. Food and Drug Administration (FDA) approved Radicava (edaravone), an innovative drug used in the treatment of amyotrophic lateral sclerosis (ALS). This was the first drug to be approved after over 20 years since the last FDA-approved drug for ALS. The approval of this drug would provide an additional option for patients suffering from this deadly disease. Increasing incidence of ALS is expected to increase the adoption rate of this drug, in turn, boosting market growth. The drug has already been approved in Japan and South Korea in 2015.

Initiatives taken by some associations to increase awareness about diagnosis and treatment of ALS among population is also expected to drive market growth during forecast period (2017-2025). For instance in 2014, the ALS Ice Bucket Challenge, a social media–centered campaign, received extensive public visibility and created increased awareness of ALS. In 2015, a group of ALS organizations in the U.S., including the ALS Association, Les Turner ALS Foundation, and ALS Therapy Development Institute, re-introduced the Ice Bucket Challenge to raise further funds and spread awareness about ALS among population.

To understand Research Methodology, please click

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy

On the basis of drug type:

  • Riluzole
  • Edaravone (Radicava)

By distribution channel:

  • Hospital Pharmacies
  • Retail & Online Pharmacies

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market – Regional Outlook

North America is expected to hold a dominant position in the amyotrophic lateral sclerosis treatment market over the forecast timeline, as major companies present in the region are focusing on collaborations for product development. For instance, in January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc. collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) for the treatment of ALS.

Companies based in the emerging economies of Asia Pacific are also focusing on developing novel drugs for treatment of ALS. For instant major companies such as Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceutical Company Ltd are developing drugs for treatment of ALS.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @

Major players are collaborating with various research institutes and companies for the development of drugs for ALS treatment

The renowned companies operating in the global amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc.

In December 2017, Mitsubishi Tanabe Pharma Corporation, Order made Medical Research Corporation and Trans Chromosomics Inc. have completed strategic collaboration for the development of antibody drug to treat neurodegenerative diseases such as ALS. In 2016, Evotec and Celgene Corporation have entered into a strategic drug discovery for the development of new drugs for neurodegenerative diseases such as ALS. Furthermore, in 2013, Janssen Research & Development, Division of Janssen Pharmaceutica NV, and Johnson & Johnson collaborated, with three prominent Belgian academic institutions and research centers for the discovery of new treatment drugs for neurodegenerative diseases such as ALS.

Table of Content

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Report
Section 1: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Overview
Section 2: Global Economic Impact on Amyotrophic Lateral Sclerosis (ALS) Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Amyotrophic Lateral Sclerosis (ALS) Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 16-Mar-2021